We could not detect significant differences across treatment arms in the change from baseline to Weeks 30 and 54 in autophagy pathways as examined by mRNA and protein levels (of HSPA6, SQSTM1/p62, MAP1LC3B, BAG1, BAG3, HSF1, HSPB1 and TFEB) and in peripheral blood mononuclear cells (PBMC) and fibroblasts of amyotrophic lateral sclerosis patients (Supplementary Tables 13 and 14; Supplementary Fig. 5). This evidence concerns the gene MAP1LC3B and amyotrophic lateral sclerosis.